Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One ...

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

The Brennan family will host the 7th Annual Dance for Dravet on September 26th at the Third Degree Glass Factory to raise ...

Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

Dravet syndrome is a type of epilepsy that starts during a child's first year. If your child has this condition, they might have seizures that last for several minutes at a time.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.5, a high estimate of $30.00, and a low estimate of $22.00. This upward trend is apparent, ...

People with Dravet syndrome experience intractable seizures throughout their lives — seizures that usually begin before they are 1 year old. What’s more, these seizures aren’t all of the ...